Comparative Study of Treatment and Potential Drug Interactions with Mental Disorders Phase at Lampung Psychiatric Hospital

https://doi.org/10.22146/jmpf.93548

Isnenia Isnenia(1*), Elma Viorentina Sembiring(2)

(1) Pharmacy Department, Health Polytechnic of Tanjung Karang, Bandar Lampung, Lampung
(2) Pharmacy Department, Health Polytechnic of Tanjung Karang, Bandar Lampung, Lampung
(*) Corresponding Author

Abstract


Background: There are some phases in mental disorders, acute, stabilization, and maintenance phase. Each phase has a different treatment goal using several types of drugs. Hospitalized patients with mental disorders are typically prescribed 5-9 drugs. Using more than one drug increase the potential for drug interactions.

Objectives: This study aims to compare treatments and potential drug interactions with the mental disorders phase at Psychiatric Hospital Lampung Province.

Methods: This study was a retrospective with a cohort design. Data were secondary in medical records and inpatient prescription sheets from January to December 2019. Purposive sampling techniques were used. The inclusion criteria in this study were all male patients hospitalized at Psychiatric Hospital Lampung Province who received and completed treatment from January to December 2019.

Results: The results showed most of 134 patients were in aged 26-35 years (27.3%), had completed high school (34.3%), were married (61.2%), and were diagnosed with paranoid schizophrenia (93.3%). Average number of medicines was 4.12 in acute phase and 3.89 in stabilization-maintenance phase. Average length of stays were 3.89 days in acute phase and 18.36 days in stabilization-maintenance phase. The second-generation antipsychotics are the most common class of drugs. There was a statistical difference (p = 0.000) for drug classes in both phases. The potential drug interactions in both phases were not significantly different (p = 0.093). The greatest severity was moderate at 88.44% in the acute phase and 94.60%  in the stabilization-maintenance phase.

Conclusion: There is a statistical difference in drug classes whereas the potential drug interactions were not.


Keywords


acute phase; drug interaction; maintenance phase; mental disorder phase; stabilization phase



References

  1. Kementerian Kesehatan RI. Laporan Nasional RISKESDAS 2018. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2019.
  2. Puspitasari AW, Angeline L. Analisis Potensi Interaksi Obat Golongan Antidepresan pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Tahun 2016. Pharm Sci Res. 2019;6(1):12-20. https://scholarhub.ui.ac.id/cgi/viewcontent.cgi?article=1009&context=psr
  3. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 54 Tahun 2017 Tentang Penanggulangan Pemasungan Pada Orang Dengan Gangguan Jiwa.; 2017.
  4. Rode SB, Ajagallay RK, Salankar HV SU. A study on drug prescribing pattern in psychiatry outpatient department from a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2014;3(3):527-522.
  5. Grover S, Nebhinani N, Chakrabarti S, et al. Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit. Indian J Psychiatry. 2016;56(4):371-376. doi:10.4103/0019-5545.146520
  6. Alosaimi FD, Alhabbad A, Abalhassan MF, et al. Patterns of psychotropic medication use in inpatient and outpatient psychiatric settings in Saudi Arabia. Neuropsychiatr Dis Treat. 2016;12:897-907. doi:10.2147/NDT.S100405
  7. Isnenia, I. Pattern of Antipsychotics in Schizophrenia Outpatients at Lampung Province Mental Hospital. Jurnal Ilmiah Medicamento. 2022; 8(1), 31–39. https://doi.org/10.36733/medicamento.v8i1.3201
  8. Shobhana, A. Drug interactions of chronic neuropsychiatric drugs in neuro-critical care. Indian Journal of Critical Care Medicine. 2019;23:157–161. https://doi.org/10.5005/jp-journals-10071-23195
  9. Sunny, S., Prabhu, S., Chand, S., UP, N., Chacko, C. S., & Joel, J. J. Assessment of drug-drug interactions among patients with psychiatric disorders: A clinical pharmacist-led study. Clinical Epidemiology and Global Health. 2022;13. 100930. https://doi.org/10.1016/j.cegh.2021.100930
  10. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically Significant Psychotropic Drug-Drug Interactions In The Primary Care Setting. Curr Psychiatry Rep. 2015;14(4):376-390. doi:10.1007/s11920-012-0284-9
  11. Lina Handayani, Febriani, Rahmadani A, Saufi A. Faktor Risiko Kejadian Skizofrenia di Rumah Sakit Grhasia, Daerah Istimewa Yogyakarta. Humanitas (Monterey N L). 2017;13(2):135-148.
  12. Pinkham AE, Harvey PD, Penn DL. Paranoid individuals with schizophrenia show greater social cognitive bias and worse social functioning than non-paranoid individuals with schizophrenia. Schizophr Res Cogn. 2016;3:33-38.
  13. Kapisa MB, Bauw SA, Yap RA. Analisis Tingkat Pendidikan dan Jenis Pekerjaan Terhadap Pendapatan Kepala Keluarga (KK) di Kampung Manbesak Distrik Biak Utara Provinsi Papua. Lensa Ekonomi. 2021;15(1):131-150
  14. Have M ten, Tuithof M, Dorsselaer S van, Schouten F, Luik AI, Graaf R de. Prevalence and trends of common mental disorders from 2007‐2009 to 2019‐2022: results from the Netherlands Mental Health Survey and Incidence Studies (NEMESIS), including comparison of prevalence rates before vs. during the COVID‐19 pandemic. World Psychiatry. 2023;22(2):275-285. doi:10.1002/wps.21087
  15. Wijaya AE, Asmin E, Satenno LBE. Tingkat Depresi dan Ansietas Pada Usia Produktif. Jurnal Ilmiah keseahtan Sandi husada. 2023;12(1):150-156
  16. Fadilla AR, Puspitasari RM. Evaluasi Ketepatan Penggunaan Antipsikotik Pada Pasien Skizofrenia Rawat Inap. Sainstech Farma. 2016;9(1):41-53.
  17. Kementerian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Jiwa.; 2015.
  18. Kusumawardhani A, Dharmono S, Diatri H, et al. Konsensus Penatalaksanaan Gangguan Skizofrenia. Perhimpunan Dokter Spesialis Kejiwaan Indonesia; 2011.
  19. Nisa A, Fitriani VY, Ibrahim A. Karakteristik Pasien Dan Pengobatan Penderita Skizofrenia Di Rsjd Atma Husada Mahakam Samarinda. J Trop Pharm Chem. 2015;2(5):292-305.
  20. Grajales D, Ferreira V, Valverde ÁM. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. Cells. 2019;8(11):1336. doi:10.3390/cells8111336
  21. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Biomed Res Int. 2014;1(1). doi:10.1155/2014/656370
  22. Utami VW, Darajati M, Puspitasari CE. Potensi interaksi obat pada pasien skizofrenia di Rumah Sakit Jiwa Mutiara Sukma tahun 2020. Sasambo J Pharm. 2022;3(1):36-42. doi:10.29303/sjp.v3i1.151
  23. Walling DP, Hassman HA, Anta L, et al. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Drug Des Dev Ther. 2021;15:4371–4382. doi:10.2147/DDDT.S332026
  24. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677.
  25. Chikowe I, Domingo M, Mwakaswaya, Shagufta VPM, Kampira C, Elizabeth. Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. BMC Res Notes. 2019;12:376-384. doi:https://doi.org/10.1186/s13104-019-4398-6
  26. Aryani F, Sari O. Gambaran Pola Penggunaan Antipsikotik Pada Pasen Skizofrenia Di Ruang Rawat Inap Rumah Sakit Jiwa. J Manaj dan Pelayanan Farm. 2016;1(1):36-43.
  27. Mousavi SG, Mirnezafat S, Tarrahi MJ. Comparison of Haloperidol, Promethazine, Trifluoperazine, and Chlorpromazine in Terms of Velocity and Durability of the Sedation among Acute Aggressive Patients: A Randomized Clinical Trial. Adv Biomed Res. 2019;8(43):1-5. doi:10.4103/abr.abr_229_18
  28. T. Yamamoto, Dargan PI, Dines A, et al. Concurrent Use of Benzodiazepine by Heroin Users—What Are the Prevalence and the Risks Associated with This Pattern of Use? J Med Toxicol. 2019;15:4-11. doi:https://doi.org/10.1007/s13181-018-0674-4
  29. Temmingh H, Stein DJ. Anxiety in Patients with Schizophrenia: Epidemiology and Management. Therapy Pract. 2015;29:819-832. doi:https://doi.org/10.1007/s40263-015-0282-7
  30. Zugliani MM, Cabo MC, Nardi AE, Perna G, Freire RC. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investig. 2019;16(1):60-69. doi:10.30773/pi.2018.12.21.1
  31. Kryst J, Majcher‑Maślanka I, Chocyk A. Efects of chronic fuoxetine treatment on anxiety and depressivelike behaviors in adolescent rodents,systematic review and meta analysis. Pharmacol Reports. 2022;74:920–946. doi:10.1007/s43440-022-00420-w
  32. Demler T, Mulcahy K. Implications of infection and trends of antibiotic prescribing in hospitalized patients diagnosed with serious mental illness. Int Clin Psychopharmacol. 2018;33(1):49-55. doi:10.1097/YIC.0000000000000193
  33. Rattanaumpawan P, Werarak P, Jitmuang A, Kiratisin P, Thamlikitkul, Visanu. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase_producing Enterobacteriaceae: an open_label randomized controlled trial. BMC Infect Dis. 2017;17(183):1-8. doi:10.1186/s12879-017-2284-1
  34. Slim M, Medina-Caliz I, Gonzalez-Jimenez A, Cabello MR, Fermin Mayoral-Cleries MIL, Andrade RJ. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. Drug Saf. 2016;39:925-943. doi:https://doi.org/10.1007/s40264-016-0436-7
  35. Telles-Correia D, Barbosa A, Cortez-Pinto H, Campo C, Rocha NBF, Machado S. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26-35. doi:10.4292/wjgpt.v8.i1.26
  36. Zaini S, Ahmad NA. Chronic Liver Disease in Patients with Schizophrenia: A Review. Malaysian J Psychiatry. 2018;17:38-49.
  37. Gunther M, Dopheide JA. Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician. J Acad Consult Psychiatry. 2023;64(1):73-84. doi:https://doi.org/10.1016/j.jaclp.2022.09.006.
  38. Goyal SK, Goel A. Successful Use of Risperidone, Trihexyphenidyl, and Paroxetine in Pregnancy. Indian J Psychol Med. 2017;39(6):835–836. doi:10.4103/IJPSYM.IJPSYM_380_17
  39. Burbuqe I, Boettger S, Schubert M, Bettex D, Rudiger A. Qtc Prolongation After Haloperidol Administration In Critically Ill Patients Post Cardiovascular Surgery: A Cohort Study And Review Of The Literature. Palliat Support Care. 2020;20(1):149. doi:10.1017/S1478951521000559.
  40. Waleekhachonloet O, Limwattananon C, Rattanachotphanit T. Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand. Ther Adv Drug Saf. 2019;10:1-6. doi:10.1177/2042098619854886



DOI: https://doi.org/10.22146/jmpf.93548

Article Metrics

Abstract views : 12

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats